PD-L1 Testing, Treatment Patterns, and Clinical Outcomes Among Patients with Metastatic NSCLC at an Academic Medical Center, 2017–2021

Introduction Targeted therapies and immune checkpoint inhibitors (ICIs) have revolutionized the management of metastatic non–small cell lung cancer (NSCLC) over the past decade. Methods This single-center observational study was conducted to describe programmed death-ligand 1 (PD-L1) testing, choice...

Full description

Saved in:

Bibliographic Details
Main Authors:	Mehmet Altan, Dawen Sui, Cai Xu, George R. Simon, Saliha T. Sulihem, Donna Malveaux, Darcy Ponce, Waree Rinsurongkawong, Vadeerat Rinsurongkawong, J. Jack Lee, Jianjun Zhang, Don L. Gibbons, Ara A. Vaporciyan, John V. Heymach, Melissa L. Santorelli, Thomas Burke, Loretta A. Williams
Format:	Article
Language:	English
Published:	Innovative Healthcare Institute 2025-04-01
Series:	Journal of Immunotherapy and Precision Oncology
Subjects:	stage iv non–small cell lung cancer immune checkpoint inhibitors overall survival pd-l1 expression targeted therapy
Online Access:	https://jipo.org/doi/pdf/10.36401/JIPO-24-26
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

PD-L1 Testing, Treatment Patterns, and Clinical Outcomes Among Patients with Metastatic NSCLC at an Academic Medical Center, 2017–2021

Similar Items